Research programme: selective androgen receptor antagonists - Biogen IdecAlternative Names: CNF 316
Latest Information Update: 24 Feb 2011
At a glance
- Originator Biogen Idec
- Mechanism of Action Heat-shock protein inhibitors; Testosterone congener inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 03 May 2006 Conforma Therapeutics has been acquired and merged into Biogen Idec
- 19 Dec 2001 Preclinical development for Prostate cancer in USA (Unknown route)